Europe Approves First Immunotherapy plus PARP Inhibitor Combination in Endometrial Cancer-Reference-Cited by-同舟云学术

Europe Approves First Immunotherapy plus PARP Inhibitor Combination in Endometrial Cancer

Published:2024-08-14 Issue: Volume: Page:
ISSN:2168-5339
Container-title:Onco Zine - The International Oncology Network
language:
Short-container-title:ONCO

Author:

,Hofland Peter^ORCID

Abstract

The European Commission has approved durvalumab (Imfinzi®; AstraZeneca)* and olaparib (Lynparza®; AstraZeneca)**, the first immunotherapy and PARP inhibitor combination, for the treatment for certain patients with primary advanced or recurrent endometrial cancer.

Publisher

Sunvalley Communication

Reference19 articles.

1. [1] Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. Erratum in: J Clin Oncol. 2024 Aug 9:JCO2401660. doi: 10.1200/JCO-24-01660. PMID: 37864337; PMCID: PMC10824389

2. [2] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. PMID: 35020204.

3. [3] Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, Lorusso D, Marth C, Makker V, Mirza MR, Ledermann JA, Colombo N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Sep;33(9):860-877. doi: 10.1016/j.annonc.2022.05.009. Epub 2022 Jun 8. PMID: 35690222.

4. [4] Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018 Aug;150(2):274-281. doi: 10.1016/j.ygyno.2018.05.018. Epub 2018 May 24. PMID: 29804638; PMCID: PMC6179372.

5. Genetic susceptibility to endometrial cancer: Risk factors and clinical management;Dork;Cancers,2020